• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Few U.S. patients with hepatitis C get timely treatment, CDC says

Shiloh

Editor, Senior Moderator
Source: https://www.reuters.com/world/us/fe...s-c-get-timely-treatment-cdc-says-2022-08-09/

Few U.S. patients with hepatitis C get timely treatment, CDC says
By Mrinalika Roy
August 9, 20221:53 PM EDTLast Updated 4 hours ago

Aug 9 (Reuters) - Few U.S. adults diagnosed with hepatitis C virus infections receive timely treatment with antiviral drugs, the U.S. Centers for Disease Control and Prevention said on Tuesday.

The drugs cure hepatitis C in more than 95% of patients, but a study of more than 47,000 adults diagnosed in 2019 or 2020 found that only one-third of those with private insurance and one-quarter of Medicaid and Medicare recipients got one of these drugs within a year, according to a report in the CDC's Vital Signs.

Treatment rates were lowest among patients in state-administered health plans, with only 23% of Medicaid recipients and 28% of Medicare recipients receiving the drugs within a year of diagnosis, the study showed. That rate was only 35% among patients with private insurance.

Lower odds of treatment were also seen in states with Medicaid restrictions and in non-white patients...
 
Back
Top